---
schema_version: "secwatch.filing_event.v1"
accession: "0001104659-25-029124"
form_type: "8-K"
ticker: "PTCT"
cik: "0001070081"
company_name: "PTC THERAPEUTICS, INC."
filed_at: "2025-03-28T23:59:59+00:00"
generated_at: "2026-05-24T02:53:13.398448+00:00"
event_type: "regulatory"
sentiment: "negative"
materiality_score: 0.9
calibrated_materiality_score: 0.9
confidence: "high"
source: SEC EDGAR
---

# European Commission refuses renewal of Translarna (ataluren) marketing authorization in EU

## Summary
- EC adopted CHMP negative opinion; renewal of conditional MA for nonsense mutation DMD denied.
- Drug effectively removed from European Economic Area; authorization ends.
- EC indicated EU member states may allow continued use under Articles 117(3) and 5(1) of Directive 2001/83.
- PTC CEO expresses disappointment; plans to work country-by-country to maintain commercial access.
- Decision based on CHMP conclusion that efficacy was not established and benefit-risk not confirmed.

## SEC filing metadata
- accession: 0001104659-25-029124
- form_type: 8-K
- ticker: PTCT
- cik: 0001070081
- company_name: PTC THERAPEUTICS, INC.
- filed_at: 2025-03-28T23:59:59+00:00
- event_type: regulatory
- sentiment: negative
- materiality_score: 0.9
- calibrated_materiality_score: 0.9
- confidence: high
- sec_items: 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1070081/000110465925029124/0001104659-25-029124-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1070081/000110465925029124/tm2510789d1_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001104659-25-029124
- JSON: https://secwatch.observer/filing/0001104659-25-029124.json
- Plain text: https://secwatch.observer/filing/0001104659-25-029124.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.